Turmoil continues at Teva Pharmaceutical Industries Ltd., which this week tried to dispel a report of company expectations of a dramatic decline in profit for its best-selling drug, and last week was suggested to be a possible takeover target by other drugmakers. On Oct. 30, chief executive officer Jeremy Levin resigned after a dispute with the board of directors, which didn’t seem to mind his departure. “In a low-interest-rate environment, Teva is now sitting in a very attractive position for an acquirer,” Bernstein Research analyst Ronny Gal wrote in a recent note to clients.
Help employers find you! Check out all the jobs and post your resume.
